Welcome to our dedicated page for Surgery Partners SEC filings (Ticker: SGRY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Surgery Partners, Inc. filings document the public-company record for a healthcare services operator focused on short-stay surgical facilities. Form 8-K reports furnish quarterly and annual results, non-GAAP reconciliations, guidance updates and Regulation FD materials related to the company’s surgical facility operations.
The filing record also covers governance and capital structure. Proxy materials describe director elections, executive compensation and stockholder voting matters, while current reports disclose debt financing through Surgery Center Holdings, Inc., supplemental indentures for senior notes, leadership appointments, employment agreements and the company’s Nasdaq-listed common stock.
Surgery Partners, Inc. (SGRY) director Teresa DeLuca reported an amended insider purchase of 11,250 shares of common stock on August 18, 2026 at a weighted average price of $14.33 per share. Following this transaction, she beneficially owns 68,093 shares directly. The amendment corrects an earlier Form 4 that had understated both the shares purchased and the price per share.
Surgery Partners, Inc. (SGRY) director Teresa DeLuca reported an open-market purchase of company stock. On 2026-08-18 she purchased 10,000 shares of common stock at a weighted average price of $14.35 per share, and now directly holds 66,843 shares of Surgery Partners common stock.
King Street Capital Management, L.P., King Street Capital Management GP, L.L.C., and Brian J. Higgins jointly report beneficial ownership of Surgery Partners, Inc. common stock on a Schedule 13G. They report 6,058,141 shares of common stock with shared voting and shared dispositive power and no sole voting or dispositive power.
This position represents 4.6% of Surgery Partners’ common stock, based on 130,918,260 shares outstanding as of August 3, 2026, as disclosed in the company’s Form 10-Q for the quarter ended June 30, 2026. King Street Capital Management acts as investment manager to various fund entities, with KSCM GP as its sole general partner and Mr. Higgins as managing member.
Surgery Partners, Inc. operates 178 surgical facilities across 30 states and reported modest top-line growth but continued losses attributable to common shareholders for the quarter ended June 30, 2026. Second‑quarter revenues were $848.9 million, up from $826.2 million a year earlier, driven by 5.0% growth in days adjusted same‑facility revenues, with a 4.8% increase in revenue per case and a 0.3% rise in same‑facility case volumes.
Cost pressures offset this growth. Cost of revenues rose to $658.7 million, 77.6% of revenues versus 76.3% last year, reflecting higher case volume, more high‑acuity procedures and increased provider taxes. Operating income declined to $102.1 million from $111.7 million, while interest expense, net, was $69.8 million, leaving income before taxes of $32.3 million. After taxes and significant earnings attributable to non‑controlling interests, net loss attributable to Surgery Partners, Inc. widened to $15.0 million versus $2.5 million.
For the first half of 2026, revenues were $1,659.8 million and Adjusted EBITDA was $227.5 million. The company held $216.7 million of cash and had $617.8 million of revolver availability, alongside $3,751.2 million of total debt. A subsequent‑events note discloses signed agreements to sell controlling interests in two hospitals for approximately $795 million of total consideration, including amounts tied to associated debt.
Surgery Partners, Inc. reported second quarter 2026 revenue of $848.9 million, up 2.7% year over year, with same-facility revenue rising 5.0% driven by a 4.8% increase in revenue per case and a modest 0.3% increase in same-facility cases. Adjusted EBITDA was $125.2 million versus $129.0 million a year ago, an Adjusted EBITDA margin of 14.7%. Net loss attributable to Surgery Partners, Inc. widened to $15.0 million, or $(0.12) per diluted share.
For the first half of 2026, revenue grew 3.6% to $1,659.8 million and Adjusted EBITDA was $227.5 million. The company ended June 30, 2026 with $216.7 million of cash, $617.8 million of undrawn revolver capacity and a total net debt to EBITDA ratio of about 4.4x. Management reaffirmed full-year 2026 guidance for revenue of $3.35–$3.45 billion and Adjusted EBITDA of at least $530 million, excluding the pending divestiture of its Idaho Falls market, which is expected to improve cash conversion and support deleveraging.
Surgery Partners, Inc. is pursuing a sale of its ownership interests in Mountain View Hospital, LLC and Idaho Falls Community Hospital, LLC to Intermountain Health. The combined Idaho Falls facilities are valued at approximately $1.15 billion, with total consideration to Surgery Partners of approximately $795 million, expected to result in substantial cash proceeds subject to customary purchase price adjustments. Signature pages to Securities Purchase Agreements have been placed into escrow, and completion depends on Mountain View Hospital physician member and governing board approvals, accuracy of representations, regulatory clearances including Hart-Scott-Rodino waiting periods, and key third-party consents.
The company characterizes this as a major step in its portfolio optimization strategy, sharpening its focus on ambulatory surgery centers while physician ownership of Mountain View Hospital remains unchanged. Excluding the impact of the transaction, Surgery Partners reaffirms its 2026 outlook for revenues of $3.35 billion to $3.45 billion and Adjusted EBITDA of at least $530 million. The Idaho Falls facilities together have 126 beds and employ over 150 physicians, offering nine surgical specialties and additional services including oncology, emergency, ICU, and neonatology.
HENDRIX BLAIR E reported acquisition or exercise transactions in this Form 4 filing.
Surgery Partners, Inc. director Blair E. Hendrix received a grant of 34,364 restricted stock awards of common stock on June 18, 2026 at $14.55 per share. These RSAs vest in three equal annual installments starting one year after the grant. After this award, Hendrix directly holds 52,895 shares of common stock.
HENDRIX BLAIR E reported acquisition or exercise transactions in this Form 4 filing.
Surgery Partners, Inc. director and ten percent owner Blair E. Hendrix received a grant of 11,670 shares of common stock on June 5, 2026 at a reference price of $13.71 per share. These shares will vest on June 5, 2027, indicating a time-based equity award rather than an immediate cash transaction.
After this award, Hendrix beneficially owns 18,531 shares of common stock directly. The filing also notes that shares previously reported as indirectly owned through Bain Capital Investors, LLC are no longer included in the total beneficially owned amount following this transaction, so the reported holdings now reflect only the direct position.
Deane John A reported acquisition or exercise transactions in this Form 4 filing.
Surgery Partners, Inc. director John A. Deane received a grant of 11,670 shares of Common Stock, valued at $13.71 per share, as equity compensation. These shares are scheduled to vest on June 5, 2027. Following this award, he directly holds 45,922 shares.
Forese Laura L reported acquisition or exercise transactions in this Form 4 filing.
Surgery Partners, Inc. director Laura L. Forese reported an award of 11,670 shares of common stock at a reference price of $13.71 per share. These shares will vest on June 5, 2027, indicating they are compensation-related rather than an open-market purchase. After this grant, her directly held position reported in this filing is 18,531 shares.